Overview: Neurofilament Immunohistochemistry TestIntroduction: The Neurofilament Immunohistochemistry Test detects neurofilament protein to diagnose neurological tumors, causing pain or numbness. Aligned with 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected neurological tumors, such as neuroblastomas.
Other Names: Neurofilament IHC Assay, Neurological Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Neurofilament testing began in the 1980s with neuroblastoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects neurofilament to diagnose neurological tumors, guides treatment, and evaluates patients with pain or numbness.
Test Parameters: 1. Neurofilament Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of pain, numbness, or neurological symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document pain, numbness, neurological deficits, or family history of neurological tumors. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect neurofilament in neurological tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for neuroblastoma or other neurological tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive neurofilament staining suggests neurological tumors (e.g., neuroblastoma), guiding surgery or chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: NSE IHC, MYCN amplification testing, or MRI to confirm neurological tumor diagnosis.
Test Limitations: Not specific to one neurological tumor; other conditions may express neurofilament. Clinical correlation is needed.
References: WHO Neuroendocrine Tumor Guidelines, 2023; American Journal of Surgical Pathology, Shimada H, 2022.
